Treating painful diabetic polyneuropathy

British Medical Journal

Volumn 335, Issue 7610, 2007, Pages 57-58

  Jude, Edward B ^a   Schaper, Nicolaas ^b  

^a TAMESIDE GENERAL HOSPITAL   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; PARACETAMOL; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ANXIETY; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DEPRESSION; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; NEUROPATHIC PAIN; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SLEEP DISORDER; SOCIAL BEHAVIOR; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; CLINICAL PROTOCOL;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL PROTOCOLS; DIABETIC NEUROPATHIES; HUMANS;

EID: 34447643400     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39261.687650.47     Document Type: Editorial

References (14)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
2. Jude E, Boulton AJM. End stage complications of diabetic neuropathy. Diabetes Rev 1999;7:395-410.
3. Vileikyte L, Rubin RR, Leventhal H. Psychological aspects of diabetic neuropathic foot complications: an overview. Misconceptions, assessment of patient beliefs and behaviour, illness perception at the individual level. Diabetes Metab Res Rev 2004;20:513-8.
4. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;21:976-82.
5. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-22.
6. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006;7:892-900.
7. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998;91:733-7.
8. Wong M, Chung JWY, Wong TKS. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ 2007 doi:10.1136/bmj.39213.565972.AE.
9. Jensen TS, Backonja MM, Hernández Jiménez S, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes Vasc Dis Res 2006;3:108-19.
10. Toelle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complicat 2006;20:26-33.
11. McCarberg B, Billington R. Consequences of neuropathic pain: quality of life issues and associated costs. Am J Manag Care 2006;12:S263-8.
12. Boulton AJM, Drury J, Clarke, Ward JD. Continous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982;5:386-90.
13. Oyibo S, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy. Diabet Med 2002;19:870-3.
14. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34.